NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
ProQR Therapeutics N.v. PRQR
11 fiscal years on record · EUR · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
€15.9M
▼ 15.9% vs FY2024
EPS · FY25
€-0.40
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-61.2%
Net margin · FY25
-265.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 15.9M
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 265 cents on every revenue dollar this year.
Per share
EUR -0.40
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-61.2%
Return on equity, FY2025
ROE
Operating margin-273.1%
Net margin-265.2%
Return on assets-30.1%
Each EUR of equity lost 61 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+64.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 112.8M
total assets, end of FY2025
Total assetsEUR 112.8M
EquityEUR 49.4M
CashEUR 92.4M
Gross debtEUR 4.9M
Net debtEUR -87.5M
Current ratio3.09×
The company holds more cash than debt.
History
11 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue €B
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Operating income €B
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA €B
·
·
·
·
·
·
·
·
·
·
·
Income tax €B
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Net income €B
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted €
−0.40
−0.32
−0.35
−0.90
−0.95
−0.93
−1.38
·
·
·
·
Dividend / sh €
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−61.2
−42.7
−51.9
−71.2
−71.1
−61.5
−60.3
−55.8
−94.4
−73.6
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed